Similar articles

• Experimental cardiac arrhythmias in the evaluation of anti-arrhythmic drugs.

  Allen JD, Ekue JM, Pantridge JF, Shanks RG, Zaidi SA. Allen JD, et al. Br J Anaesth. 1971 Jul;43(7):720-1. Br J Anaesth. 1971. PMID: 4398093 No abstract available.
• Mechanism of action of a new adrenergic beta-receptor antagonist MJ 1999 in the prevention of halothane-adrenaline-induced and ouabain-induced ventricular tachycardia in the dog.

  Sharma PL. Sharma PL. Indian J Med Res. 1967 Dec;55(12):1357-65. Indian J Med Res. 1967. PMID: 5595584 No abstract available.
• Antiarrhythmic actions of two new beta adrenergic blocking agents, Kö 1313 and Kö 1366.

  Baum T, Rowles G, Shropshire AT. Baum T, et al. J Pharmacol Exp Ther. 1971 Feb;176(2):350-60. J Pharmacol Exp Ther. 1971. PMID: 4105546 No abstract available.
• Role of imidazoline receptors in halothane-epinephrine arrhythmias.

  Hayashi Y, Kamibayashi T, Yamatodani A, Kuro M, Yoshiya I. Hayashi Y, et al. Ann N Y Acad Sci. 1995 Jul 12;763:610-9. doi: 10.1111/j.1749-6632.1995.tb32456.x. Ann N Y Acad Sci. 1995. PMID: 7677381 Review. No abstract available.
• Assessment of antiarrhythmic drugs in experimental pharmacology.

  Caillard CG, Louis JC. Caillard CG, et al. Methods Find Exp Clin Pharmacol. 1980 Oct;2(5):223-52. Methods Find Exp Clin Pharmacol. 1980. PMID: 6765586 Review. No abstract available.